Related Experiment Videos
Critical appraisals of approaches for predictive designs in anticancer drugs
1Department of Chemistry, University of Wisconsin-Milwaukee, 53201, USA.
Abstract:
The present review provides a critical appraisal of the most important areas in cancer drug research and, ultimately, in clinical oncology and therapy, with emphasis on the elucidation of possible predictive designs for the development of new anticancer drugs. These assessments encompass the well-established anticancer drugs and congeners which have been employed over the years in clinical therapy, and the more recent exploratory agents still requiring further rigorous scrutiny in the clinical environment. These areas mainly include the bioreversible redox carriers, the boron neutron capture compounds, some new mitosis-interactive agents, cell cycle modifiers, biological-response mpdifiers, oncogene inhibitors, drug-antibody conjugates, cancer cell suppression and destruction agents, antiangiogenesis and antimetastasis agents, apoptosis-promoting agents, and gene therapy and vaccines.
Insights
This review critically appraises key cancer drug research areas and predictive designs for novel anticancer therapies. It covers established and emerging agents, including targeted therapies and immunotherapies, for improved clinical oncology outcomes.
Area of Science:
- Oncology
- Pharmacology
- Drug Development
Background:
- Cancer drug research is crucial for advancing clinical oncology and therapy.
- Established anticancer drugs and novel exploratory agents require continuous evaluation.
Purpose of the Study:
- To critically appraise key areas in cancer drug research.
- To elucidate predictive designs for developing new anticancer drugs.
- To review both established and emerging anticancer agents.
Main Methods:
- Comprehensive literature review of existing and novel anticancer agents.
- Analysis of predictive design strategies in drug development.
- Assessment of agents across various therapeutic classes.
Main Results:
- Identified key areas including bioreversible redox carriers, boron neutron capture compounds, mitosis-interactive agents, cell cycle modifiers, and biological-response modifiers.
- Highlighted oncogene inhibitors, drug-antibody conjugates, and cancer cell suppression agents.
- Reviewed antiangiogenesis, antimetastasis, apoptosis-promoting agents, gene therapy, and vaccines.
Conclusions:
- The review provides a critical assessment of current and future directions in anticancer drug development.
- Emphasis is placed on predictive designs to guide the creation of more effective cancer therapies.
- A broad spectrum of therapeutic strategies is essential for combating cancer effectively.